— Know what they know.
Not Investment Advice

PTCT NASDAQ

PTC Therapeutics, Inc.
1W: -4.0% 1M: -1.5% 3M: -1.2% YTD: -9.1% 1Y: +47.9% 3Y: +28.8% 5Y: +83.7%
$68.81
-0.98 (-1.40%)
 
Weekly Expected Move ±9.4%
$58 $65 $71 $78 $85
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 52 · $5.7B mcap · 73M float · 1.70% daily turnover · Short 70% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
38.7 / 100
NoneWeakNarrowWide
Primary source: Cost Advantage  ·  ROIC: 3.2%
Cost Advantage ★
58
Intangibles
33
Switching Cost
31
Network Effect
47
Scale
27
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. PTCT has No discernible competitive edge (38.7/100). The business operates without significant structural advantages. The primary source of advantage is Cost Advantage. ROIC of 3.2% suggests modest returns relative to capital deployed.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$94
Low
$94
Avg Target
$94
High
Based on 1 analyst since May 7, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 16Hold: 8Sell: 2Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$103.50
Analysts4
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-05-08 Morgan Stanley Judah Frommer $92 $94 +2 +24.7% $75.36
2026-04-10 Raymond James Tiago Fauth Initiated $108 +56.3% $69.11
2026-02-23 Morgan Stanley $90 $92 +2 +30.2% $70.66
2026-02-23 Barclays Eliana Merle $119 $120 +1 +69.8% $70.66
2026-02-20 RBC Capital Brian Abrahams $91 $82 -9 +20.7% $67.94
2026-02-20 Wells Fargo $93 $86 -7 +23.0% $69.90
2026-01-27 Barclays $68 $119 +51 +57.6% $75.49
2026-01-08 Morgan Stanley $45 $90 +45 +16.5% $77.24
2025-12-01 RBC Capital $58 $91 +33 +5.8% $85.99
2025-11-05 Goldman Sachs $32 $50 +18 -30.4% $71.79
2025-11-05 Wells Fargo Tiago Fauth Initiated $93 +37.3% $67.72
2025-11-05 Barclays Gena Wang Initiated $68 +0.4% $67.72
2025-10-28 Jefferies Kelly Shi $46 $77 +31 +13.5% $67.86
2025-08-08 Robert W. Baird Joel Beatty $66 $70 +4 +54.3% $45.38
2025-05-07 Robert W. Baird Joel Beatty $52 $66 +14 +82.4% $36.19
2025-01-07 RBC Capital Brian Abrahams $46 $58 +12 +30.0% $44.61
2024-11-27 Robert W. Baird Joel Beatty Initiated $52 +15.3% $45.09
2024-10-11 Morgan Stanley Jeffrey Hung $32 $45 +13 +16.9% $38.48
2024-08-26 UBS Colin Bristow $45 $47 +2 +34.3% $34.99
2024-07-12 Morgan Stanley Jeffrey Hung $30 $32 +2 -3.6% $33.20
2024-05-20 Goldman Sachs Paul Choi $35 $32 -3 -20.2% $40.12
2024-05-20 Jefferies Kelly Shi Initiated $46 +15.5% $39.81
2024-04-26 Morgan Stanley Jeffrey Hung Initiated $30 +5.0% $28.57
2022-12-14 Goldman Sachs Initiated $35 -10.1% $38.94
2022-06-23 RBC Capital Brian Abrahams Initiated $46 +20.1% $38.29
2022-04-04 Cantor Fitzgerald Kristen Kluska Initiated $63 +44.4% $43.64
2021-08-30 UBS Colin Bristow Initiated $45 +3.1% $43.65

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C
May 22, 2026
DCF
1
ROE
5
ROA
1
D/E
1
P/E
1
P/B
1
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. PTCT receives an overall rating of C. Strongest factors: ROE (5/5). Areas of concern: DCF (1/5), ROA (1/5), D/E (1/5), P/E (1/5), P/B (1/5).
Rating Change History
DateFromTo
2026-05-08 C+ C

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

9 Grade D
Profitability
30
Balance Sheet
42
Earnings Quality
58
Growth
12
Value
32
Momentum
20
Safety
15
Cash Flow
20
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. PTCT scores highest in Earnings Quality (58/100) and lowest in Growth (12/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
0.40
Distress Zone
Piotroski F-Score
2/9
Beneish M-Score
0.24
Possible Manipulator
Ohlson O-Score
-5.26
Bankruptcy prob: 0.5%
Low Risk
Credit Rating
B-
Score: 20.0/100
Trend: Stable
Earnings Quality
OCF/NI: 1.17x
Accruals: 1.4%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. PTCT scores 0.40, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. PTCT scores 2/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. PTCT's score of 0.24 exceeds the −1.78 red flag threshold — this does not confirm manipulation but indicates the earnings profile resembles past manipulators statistically. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. PTCT's implied 0.5% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. PTCT receives an estimated rating of B- (score: 20.0/100), with a stable trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-30.41x
PEG
0.23x
P/S
6.90x
P/B
-31.46x
P/FCF
-24.56x
P/OCF
EV/EBITDA
-187.98x
EV/Revenue
5.04x
EV/EBIT
-60.26x
EV/FCF
-18.21x
Earnings Yield
-3.32%
FCF Yield
-4.07%
Shareholder Yield
0.00%
Graham Number
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. PTCT currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.792
NI / EBT
×
Interest Burden
3.406
EBT / EBIT
×
EBIT Margin
-0.084
EBIT / Rev
×
Asset Turnover
0.358
Rev / Assets
×
Equity Multiplier
-3.542
Assets / Equity
=
ROE
28.7%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. PTCT's ROE of 28.7% is driven by Asset Turnover (0.358), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
Price/Value
Margin of Safety
Premium
Assessment
Overvalued

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$68.81
Median 1Y
$65.31
5th Pctile
$27.63
95th Pctile
$153.67
Ann. Volatility
53.8%
Analyst Target
$103.50
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Matthew B. Klein
Chief Executive Officer ​
$958,500 $16,593,800 $23,266,326
Eric Pauwels
Chief Business Officer ​
$613,150 $1,023,880 $3,562,968
Pierre Gravier
Chief Financial Officer ​
$579,167 $1,047,150 $3,550,786
Lee Golden
Executive Vice President and Chief Medical Officer ​
$574,667 $930,800 $3,269,179
Neil Almstead
Chief Technical Operations Officer ​
$582,500 $884,260 $3,159,055

CEO Pay Ratio

3887:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $23,266,326
Avg Employee Cost (SGA/emp): $5,985
Employees: 58,000

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
58,000
+5700.0% YoY
Revenue / Employee
$29,839
Rev: $1,730,655,000
Profit / Employee
$11,770
NI: $682,644,000
SGA / Employee
$5,985
Avg labor cost proxy
R&D / Employee
$7,849
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
ROE -72.7% -84.5% -2.2% -2.2% -2.3% -2.2% 3.2% 3.3% 3.6% 3.7% 1.1% 99.4% 82.3% 77.8% 37.9% -62.1% -65.7% -78.4% -1.0% 28.7% 28.65%
ROA -20.4% -23.7% -25.3% -25.2% -26.8% -25.6% -30.7% -31.4% -33.9% -35.2% -34.8% -32.2% -26.6% -25.2% -20.2% 33.0% 34.9% 41.8% 29.6% -8.1% -8.09%
ROIC 1.4% 1.5% -59.5% -57.6% -56.6% -53.5% -50.8% -54.3% -67.5% -72.5% -65.4% -54.8% -29.7% -20.3% -1.0% 2.8% 2.9% 3.4% -50.6% 3.2% 3.22%
ROCE -13.9% -18.3% -30.3% -29.5% -31.7% -31.3% -38.2% -38.9% -45.2% -47.7% -43.9% -38.9% -26.1% -19.7% -17.4% 72.2% 72.3% 78.2% 43.7% -3.6% -3.56%
Gross Margin 93.7% 95.3% 94.4% 93.2% 94.2% 93.5% 93.5% 93.6% 94.0% 95.2% 65.4% 93.0% 91.7% 94.5% 92.4% 98.9% 93.6% 45.1% 90.1% 85.5% 85.47%
Operating Margin -84.4% -67.1% -51.3% -58.2% -55.8% -33.8% -1.2% -53.4% -98.0% -60.1% 1.0% -21.6% -21.5% -27.7% -76.2% 82.5% -19.5% 1.4% -49.6% 16.8% 16.84%
Net Margin -1.0% -96.3% -86.7% -85.2% -91.9% -50.3% -1.0% -63.1% -93.0% -67.6% -50.7% -43.6% -53.1% -54.2% -30.9% 73.7% -36.3% 7.5% -82.0% -1.0% -1.03%
EBITDA Margin -68.9% -68.5% -58.9% -48.5% -58.9% -31.6% -75.5% -29.4% -73.5% -37.6% -10.4% 5.5% -18.9% -25.4% -22.0% 82.6% -18.5% 9.8% -43.1% 22.5% 22.49%
FCF Margin -52.9% -66.4% -62.5% -69.5% -68.3% -58.7% -72.9% -52.4% -44.4% -43.0% -29.8% -21.5% -25.6% -30.4% -22.6% 38.3% 38.6% 39.3% 40.4% -27.7% -27.68%
OCF Margin -35.8% -50.2% -46.7% -43.7% -44.1% -37.3% -51.0% -37.5% -30.2% -28.1% -16.9% -6.3% -12.8% -19.8% -13.3% 39.0% 39.9% 40.2% 41.1% -26.4% -26.35%
ROA 3Y Avg snapshot only -0.69%
ROIC Economic snapshot only -19.77%
Cash ROA snapshot only -7.49%
NOPAT Margin snapshot only -6.46%
Pretax Margin snapshot only -28.49%
R&D / Revenue snapshot only 54.06%
SGA / Revenue snapshot only 43.04%
SBC / Revenue snapshot only 4.59%
Valuation
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
P/E Ratio -7.61 -5.77 -5.37 -5.09 -5.15 -6.77 -4.96 -6.25 -4.92 -2.63 -3.32 -3.84 -4.89 -6.30 -9.59 7.40 6.07 7.11 8.98 -30.11 -30.409
P/S Ratio 6.31 5.34 5.23 4.67 4.62 5.16 3.97 4.64 3.71 2.12 2.22 2.40 2.61 3.17 4.32 2.48 2.16 3.00 3.54 6.80 6.901
P/B Ratio 6.18 5.45 1957.43 1847.73 1988.32 2501.44 -7.99 -10.29 -8.76 -4.87 -2.54 -2.72 -2.87 -3.49 -3.17 -4.01 -3.48 -4.87 -29.85 -27.38 -31.465
P/FCF -11.91 -8.03 -8.36 -6.72 -6.78 -8.79 -5.45 -8.85 -8.36 -4.92 -7.46 -11.16 -10.19 -10.41 -19.15 6.48 5.61 7.65 8.77 -24.56 -24.555
P/OCF 6.36 5.42 7.47 8.62
EV/EBITDA -10.64 -6.57 -8.99 -9.14 -9.27 -12.20 -10.49 -12.94 -9.81 -6.49 -10.47 -14.23 -28.53 -39.81 -39.98 6.83 6.12 7.32 5.27 -187.98 -187.982
EV/Revenue 4.86 3.95 6.15 5.54 5.43 5.88 5.47 6.00 5.00 3.43 3.66 3.86 4.11 4.67 5.97 3.23 2.92 3.75 2.70 5.04 5.041
EV/EBIT -8.55 -5.50 -7.66 -7.48 -7.41 -9.15 -7.70 -9.14 -6.96 -4.42 -6.06 -7.11 -10.97 -16.48 -24.56 7.06 6.33 7.60 5.51 -60.26 -60.260
EV/FCF -9.18 -5.94 -9.83 -7.97 -7.95 -10.01 -7.51 -11.46 -11.25 -7.98 -12.30 -17.94 -16.07 -15.34 -26.47 8.44 7.56 9.55 6.69 -18.21 -18.209
Earnings Yield -13.1% -17.3% -18.6% -19.6% -19.4% -14.8% -20.2% -16.0% -20.3% -38.0% -30.1% -26.0% -20.4% -15.9% -10.4% 13.5% 16.5% 14.1% 11.1% -3.3% -3.32%
FCF Yield -8.4% -12.5% -12.0% -14.9% -14.8% -11.4% -18.4% -11.3% -12.0% -20.3% -13.4% -9.0% -9.8% -9.6% -5.2% 15.4% 17.8% 13.1% 11.4% -4.1% -4.07%
PEG Ratio snapshot only 0.232
EV/Gross Profit snapshot only 6.475
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Current Ratio 4.44 4.44 1.87 1.87 1.87 1.87 1.71 1.71 1.71 1.71 2.02 2.02 2.02 2.02 2.35 2.35 2.35 2.35 2.35 2.35 2.348
Quick Ratio 4.37 4.37 1.84 1.84 1.84 1.84 1.65 1.65 1.65 1.65 1.97 1.97 1.97 1.97 2.31 2.31 2.31 2.31 2.27 2.27 2.266
Debt/Equity 0.87 0.87 882.73 882.73 882.73 882.73 -4.21 -4.21 -4.21 -4.21 -2.72 -2.72 -2.72 -2.72 -2.25 -2.25 -2.25 -2.25 -2.40 -2.40 -2.398
Net Debt/Equity -1.42 -1.42 344.92 344.92 344.92 344.92
Debt/Assets 0.19 0.19 0.65 0.65 0.65 0.65 0.86 0.86 0.86 0.86 1.18 1.18 1.18 1.18 1.45 1.45 1.45 1.45 0.17 0.17 0.169
Debt/EBITDA -1.95 -1.42 -3.45 -3.68 -3.51 -3.78 -4.01 -4.09 -3.51 -3.46 -6.80 -8.86 -17.19 -21.10 -20.51 2.94 2.94 2.71 0.55 -22.20 -22.197
Net Debt/EBITDA 3.17 2.31 -1.35 -1.44 -1.37 -1.48 -2.88 -2.94 -2.52 -2.49 -4.12 -5.38 -10.43 -12.80 -11.05 1.59 1.58 1.46 -1.64 65.52 65.519
Interest Coverage -3.08 -4.03 -5.03 -4.67 -5.05 -5.04 -5.47 -5.34 -5.75 -5.66 -4.39 -3.53 -2.15 -1.50 -1.17 5.06 5.53 6.37 5.58 -1.00 -1.001
Equity Multiplier 4.58 4.58 1347.74 1347.74 1347.74 1347.74 -4.91 -4.91 -4.91 -4.91 -2.32 -2.32 -2.32 -2.32 -1.55 -1.55 -1.55 -1.55 -14.18 -14.18 -14.180
Cash Ratio snapshot only 2.009
Debt Service Coverage snapshot only -0.321
Cash to Debt snapshot only 3.952
FCF to Debt snapshot only -0.465
Defensive Interval snapshot only 1091.1 days
Efficiency & Turnover
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Asset Turnover 0.25 0.26 0.26 0.27 0.30 0.34 0.38 0.42 0.45 0.44 0.52 0.52 0.50 0.50 0.45 0.98 0.98 0.99 0.75 0.36 0.358
Inventory Turnover 1.37 1.47 1.87 1.93 2.06 2.50 2.37 2.59 2.75 2.51 5.45 5.47 5.58 5.63 2.13 2.07 1.91 5.82 3.04 3.56 3.564
Receivables Turnover 7.52 7.85 5.97 6.31 6.85 7.72 5.25 5.79 6.15 6.00 5.93 5.86 5.69 5.69 5.05 11.10 11.05 11.14 10.18 4.86 4.863
Payables Turnover 1.79 1.92 1.55 1.60 1.71 2.07 1.78 1.94 2.06 1.88 8.56 8.60 8.77 8.85 4.92 4.76 4.41 13.42 4.99 5.84 5.840
DSO 49 47 61 58 53 47 69 63 59 61 62 62 64 64 72 33 33 33 36 75 75.1 days
DIO 266 249 195 189 177 146 154 141 133 145 67 67 65 65 171 177 191 63 120 102 102.4 days
DPO 203 190 235 228 214 177 205 189 177 194 43 42 42 41 74 77 83 27 73 62 62.5 days
Cash Conversion Cycle 112 105 21 19 17 17 18 16 15 12 86 87 88 88 169 133 141 68 83 115 115.0 days
Fixed Asset Turnover snapshot only 6.108
Operating Cycle snapshot only 177.5 days
Cash Velocity snapshot only 0.425
Capital Intensity snapshot only 3.520
Growth (YoY)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 51.6% 37.4% 41.4% 32.3% 31.0% 41.5% 29.7% 35.3% 32.4% 14.6% 34.2% 20.4% 10.0% 12.8% -14.0% 91.1% 96.0% 97.5% 1.1% -53.3% -53.34%
Net Income 9.4% -3.1% -19.6% -14.9% -42.1% -16.8% -6.7% -9.4% -11.2% -20.8% -12.1% -1.4% 22.4% 29.4% 42.0% 2.0% 2.3% 2.7% 2.9% -1.3% -1.31%
EPS 16.2% 1.2% -13.1% -13.3% -40.2% -15.1% -3.8% -5.7% -6.2% -14.8% -7.9% 2.3% 24.4% 30.8% 43.3% 1.9% 2.3% 2.5% 2.8% -1.3% -1.33%
FCF -8.5% -61.8% -30.0% -41.2% -68.9% -25.1% -51.2% -2.0% 13.8% 16.1% 45.2% 50.6% 36.7% 20.1% 34.8% 4.4% 4.0% 3.5% 4.8% -1.3% -1.34%
EBITDA 40.8% 10.1% -21.5% -14.6% -68.0% -13.4% 1.0% -3.6% -15.2% -25.8% 10.1% 29.6% 68.9% 75.0% 63.3% 4.3% 7.5% 9.6% 8.4% -1.0% -1.03%
Op. Income 15.8% 5.4% 13.3% 17.0% -2.5% 12.7% -20.9% -33.3% -68.5% -91.5% 2.3% 23.5% 66.6% 78.8% 31.6% 2.9% 4.6% 6.7% 3.8% -1.1% -1.09%
OCF Growth snapshot only -1.32%
Asset Growth snapshot only 70.75%
Debt Growth snapshot only -80.08%
Shares Change snapshot only -4.47%
Growth (CAGR)
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue 3Y 24.5% 24.3% 26.7% 29.5% 30.4% 32.9% 31.5% 33.8% 38.0% 30.6% 35.0% 29.2% 24.0% 22.3% 14.4% 46.0% 41.9% 36.7% 35.3% 2.4% 2.39%
Revenue 5Y 52.6% 47.6% 45.5% 44.5% 38.2% 37.5% 29.2% 28.0% 27.3% 25.5% 28.8% 28.7% 26.4% 24.9% 21.3% 40.7% 41.5% 37.8% 35.4% 14.0% 13.95%
EPS 3Y
EPS 5Y
Net Income 3Y
Net Income 5Y
EBITDA 3Y
EBITDA 5Y
Gross Profit 3Y 23.8% 23.7% 26.2% 28.9% 29.8% 31.9% 30.4% 32.9% 37.4% 30.1% 30.0% 24.5% 19.2% 17.5% 14.0% 47.4% 43.3% 35.4% 34.0% -3.7% -3.74%
Gross Profit 5Y 1.6% 54.9% 41.8% 28.1% 27.3% 26.7% 25.1% 25.8% 25.7% 23.1% 21.5% 20.5% 41.0% 42.1% 36.6% 34.2% 9.6% 9.63%
Op. Income 3Y
Op. Income 5Y
FCF 3Y
FCF 5Y
OCF 3Y
OCF 5Y
Assets 3Y 78.0% 78.0% 20.1% 20.1% 20.1% 20.1% 1.7% 1.7% 1.7% 1.7% -5.0% -5.0% -5.0% -5.0% -4.2% -4.2% -4.2% -4.2% 19.5% 19.5% 19.51%
Assets 5Y 43.1% 43.1% 48.4% 48.4% 48.4% 48.4% 34.2% 34.2% 34.2% 34.2% 11.1% 11.1% 11.1% 11.1% 1.0% 1.0% 1.0% 1.0% 5.7% 5.7% 5.68%
Equity 3Y 45.5% 45.5% -84.0% -84.0% -84.0% -84.0%
Book Value 3Y 26.4% 28.0% -85.7% -85.2% -85.2% -85.2%
Dividend 3Y
Growth Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Revenue Stability 0.94 0.98 0.97 0.98 0.95 0.94 0.93 0.92 0.90 0.94 0.92 0.97 0.98 0.98 0.86 0.80 0.81 0.78 0.75 0.36 0.363
Earnings Stability 0.61 0.70 0.83 0.90 0.88 0.91 0.96 0.97 0.92 0.94 0.94 0.91 0.60 0.50 0.20 0.22 0.33 0.37 0.43 0.30 0.302
Margin Stability 0.00 0.00 0.10 0.48 0.78 0.93 0.98 0.99 0.99 0.99 0.95 0.95 0.95 0.95 0.95 0.95 0.94 0.95 0.96 0.91 0.911
Rev. Growth Consistency 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 1.00 1.00 0.50 0.00 0.000
Earn. Growth Consistency 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence 0.96 0.99 0.92 0.94 0.83 0.93 0.97 0.96 0.96 0.92 0.95 0.99 0.91 0.88 0.83 0.20 0.20 0.20 0.20 0.20 0.200
Earnings Smoothness
ROE Trend -0.14 -0.26 -363.66 -362.28 -385.67 -368.69
Gross Margin Trend -0.01 -0.01 -0.02 -0.01 -0.00 -0.01 -0.01 -0.01 -0.01 0.00 -0.09 -0.09 -0.10 -0.10 0.04 0.08 0.08 0.02 0.02 -0.13 -0.129
FCF Margin Trend 0.05 -0.14 -0.05 -0.06 -0.05 0.03 -0.08 0.15 0.16 0.20 0.38 0.39 0.31 0.20 0.29 0.75 0.74 0.76 0.67 -0.36 -0.361
Sustainable Growth Rate
Internal Growth Rate 49.3% 53.7% 71.7% 42.0%
Cash Flow Quality
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
OCF/Net Income 0.43 0.54 0.48 0.48 0.49 0.49 0.64 0.51 0.40 0.35 0.25 0.10 0.24 0.39 0.30 1.16 1.12 0.95 1.04 1.17 1.167
FCF/OCF 1.48 1.32 1.34 1.59 1.55 1.58 1.43 1.40 1.47 1.53 1.76 3.43 1.99 1.54 1.69 0.98 0.97 0.98 0.98 1.05 1.051
FCF/Net Income snapshot only 1.226
CapEx/Revenue 17.1% 16.3% 15.8% 25.8% 24.1% 21.5% 21.8% 14.9% 14.2% 14.9% 12.9% 15.2% 12.7% 10.7% 9.2% 0.7% 1.3% 0.9% 0.7% 1.3% 1.33%
CapEx/Depreciation snapshot only 0.234
Accruals Ratio -0.12 -0.11 -0.13 -0.13 -0.14 -0.13 -0.11 -0.16 -0.20 -0.23 -0.26 -0.29 -0.20 -0.15 -0.14 -0.05 -0.04 0.02 -0.01 0.01 0.014
Sloan Accruals snapshot only 0.205
Cash Flow Adequacy snapshot only -19.796
Dividends & Buybacks
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio 0.0% 0.0% 0.0% 0.0%
FCF Payout Ratio 0.0% 0.0% 0.0% 0.0%
Total Payout Ratio 0.0% 0.0% 0.0% 0.0%
Div. Increase Streak
Chowder Number
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -0.8% -1.0% -1.1% -0.8% -1.3% -1.2% -1.23%
Total Shareholder Return -0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -0.8% -1.0% -1.1% -0.8% -1.3% -1.2% -1.23%
DuPont Factors
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Tax Burden (NI/EBT) 1.10 1.03 1.01 1.02 1.02 0.99 0.95 0.95 0.90 0.88 0.90 0.90 0.97 1.07 1.00 0.91 0.94 1.01 0.98 0.79 0.792
Interest Burden (EBT/EBIT) 1.32 1.25 1.20 1.21 1.20 1.20 1.18 1.19 1.17 1.18 1.23 1.28 1.46 1.67 1.85 0.80 0.82 0.84 0.82 3.41 3.406
EBIT Margin -0.57 -0.72 -0.80 -0.74 -0.73 -0.64 -0.71 -0.66 -0.72 -0.78 -0.60 -0.54 -0.37 -0.28 -0.24 0.46 0.46 0.49 0.49 -0.08 -0.084
Asset Turnover 0.25 0.26 0.26 0.27 0.30 0.34 0.38 0.42 0.45 0.44 0.52 0.52 0.50 0.50 0.45 0.98 0.98 0.99 0.75 0.36 0.358
Equity Multiplier 3.56 3.56 8.58 8.58 8.58 8.58 -10.54 -10.54 -10.54 -10.54 -3.09 -3.09 -3.09 -3.09 -1.88 -1.88 -1.88 -1.88 -3.54 -3.54 -3.542
Per Share
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
EPS (Diluted TTM) $-5.55 $-6.45 $-7.41 $-7.33 $-7.79 $-7.42 $-7.69 $-7.75 $-8.27 $-8.51 $-8.30 $-7.57 $-6.25 $-5.89 $-4.71 $6.89 $8.05 $8.63 $8.46 $-2.26 $-2.26
Book Value/Share $6.84 $6.83 $0.02 $0.02 $0.02 $0.02 $-4.78 $-4.71 $-4.64 $-4.60 $-10.84 $-10.70 $-10.67 $-10.64 $-14.22 $-12.71 $-14.05 $-12.60 $-2.54 $-2.49 $-2.19
Tangible Book/Share $-4.48 $-4.47 $-11.40 $-11.31 $-11.29 $-11.24 $-15.63 $-15.40 $-15.19 $-15.06 $-16.96 $-16.74 $-16.69 $-16.64 $-16.83 $-15.04 $-16.62 $-14.91 $-8.38 $-8.20 $-8.20
Revenue/Share $6.70 $6.97 $7.62 $8.00 $8.66 $9.72 $9.62 $10.45 $10.96 $10.59 $12.42 $12.13 $11.74 $11.71 $10.45 $20.52 $22.58 $20.42 $21.45 $10.02 $10.02
FCF/Share $-3.55 $-4.63 $-4.76 $-5.55 $-5.91 $-5.71 $-7.01 $-5.47 $-4.87 $-4.55 $-3.70 $-2.61 $-3.00 $-3.56 $-2.36 $7.86 $8.71 $8.02 $8.66 $-2.77 $-2.77
OCF/Share $-2.40 $-3.50 $-3.56 $-3.49 $-3.82 $-3.62 $-4.91 $-3.92 $-3.31 $-2.97 $-2.10 $-0.76 $-1.51 $-2.31 $-1.39 $8.01 $9.02 $8.21 $8.81 $-2.64 $-2.64
Cash/Share $15.67 $15.64 $10.94 $10.86 $10.84 $10.79 $5.65 $5.57 $5.50 $5.45 $11.61 $11.46 $11.43 $11.40 $14.76 $13.19 $14.58 $13.08 $24.11 $23.57 $22.93
EBITDA/Share $-3.06 $-4.19 $-5.21 $-4.84 $-5.07 $-4.68 $-5.02 $-4.85 $-5.58 $-5.60 $-4.34 $-3.29 $-1.69 $-1.37 $-1.56 $9.71 $10.76 $10.47 $11.00 $-0.27 $-0.27
Debt/Share $5.97 $5.96 $17.96 $17.82 $17.78 $17.72 $20.12 $19.82 $19.56 $19.39 $29.52 $29.14 $29.05 $28.98 $32.01 $28.61 $31.62 $28.37 $6.10 $5.97 $5.97
Net Debt/Share $-9.70 $-9.68 $7.02 $6.96 $6.95 $6.92 $14.46 $14.25 $14.06 $13.94 $17.91 $17.68 $17.63 $17.58 $17.25 $15.41 $17.04 $15.28 $-18.01 $-17.61 $-17.61
Academic Models
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Altman Z-Score 0.401
Altman Z-Prime snapshot only 1.357
Piotroski F-Score 6 5 2 3 3 2 2 3 2 3 4 5 5 5 4 7 7 5 6 2 2
Beneish M-Score -2.61 -2.70 -2.62 -2.66 -2.65 -2.56 -2.67 -2.84 -3.13 -3.23 -3.13 -3.86 -3.45 -3.26 -3.57 0.46 -3.00 -2.06 -2.10 0.24 0.244
Ohlson O-Score snapshot only -5.262
Net-Net WC snapshot only $-10.21
Credit
Metric Trend Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Current
Credit Rating snapshot only B-
Credit Score 33.05 33.49 18.35 18.70 18.66 19.06 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.000
Credit Grade snapshot only 16
Credit Trend snapshot only 0.000
Implied Spread (bps) snapshot only 900.000
Industry Credit Rank snapshot only 19
Sector Credit Rank snapshot only 19

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms